IDH2 and central nervous system cancer: An integrated genomic analysis found recurrent heterozygous mutations in the active site of IDH1 and IDH2 isoforms in high proportion of low-grade glioma and acute myeloid leukemia (AML) patients (Parsons et al, 2008; Mardis et al, 2009; Yen et al, 2010).